Opinion
Video
“I truly think genetic testing should be incorporated as a part of daily care in prostate cancer,” says Joy Maulik, CRNP.
Genetic testing can have a profound impact on prostate cancer treatment decisions, yet urologists are not ordering it nearly enough, says Joy Maulik, CRNP. In an interview at the 2025 American Urological Association (AUA) Annual Meeting in Las Vegas, Nevada, Maulik touched on the importance of genetic testing for these patients.
In his view, germline and somatic testing, in addition to PSMA-PET imaging, can offer a chance to detect and treat disease early, thus extending life.
“I truly think genetic testing should be incorporated as a part of daily care in prostate cancer,” Maulik noted, “If we don't do it, I think we are not taking care of the patient the right way that we need to.”
Maulik is a urology nurse practitioner at Chesapeake Urology in Salisbury, Maryland.
Maulik also touched on the idea of understanding a wide range of guideline recommendations.
“We should be looking at what NCCN guidelines are. We should be looking at what EUA is doing, because cancer doesn't have emotion. No matter which continent it's hitting you, it's hitting you.”